{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:31:23Z","timestamp":1791217883413,"version":"4.1.0"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00506","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T04:48:14Z","timestamp":1588913294000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["Biological Difference Between Epstein\u2013Barr Virus Positive and Negative Post-transplant Lymphoproliferative Disorders and Their Clinical Impact"],"prefix":"10.3389","volume":"10","author":[{"given":"Valeria","family":"Ferla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Gaia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cecilia","family":"Goldaniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,8]]},"reference":[{"key":"B1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"B2","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/j.1600-6143.2011.03499.x","article-title":"Epstein-Barr Virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy","volume":"11","author":"Nourse","year":"2011","journal-title":"Am J Transplant"},{"key":"B3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s11864-011-0177-x","article-title":"Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations","volume":"13","author":"Jagadeesh","year":"2012","journal-title":"Curr Treat Options Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1097\/00007890-199911270-00015","article-title":"Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS\/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting","volume":"68","author":"Paya","year":"1999","journal-title":"Transplantation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/j.1600-6143.2008.02167.x","article-title":"Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids","volume":"8","author":"McDonald","year":"2008","journal-title":"Am J Transplant"},{"key":"B6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1046\/j.1365-2141.2001.02740.x","article-title":"Post renal transplantation human herpesvirus 8-associated lymphoproliferative disorder and Kaposi's sarcoma","volume":"113","author":"Kapelushnik","year":"2001","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1128\/JVI.68.9.6069-6073.1994","article-title":"Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV","volume":"68","author":"Shimizu","year":"1994","journal-title":"J Virol."},{"key":"B8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/annonc\/8.suppl_2.S131","article-title":"Integration of Epstein-Barr virus in Burkitt's lymphoma cells leads to a region of enhanced chromosome instability","volume":"8","author":"Jox","year":"1997","journal-title":"Ann Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0002-9440(10)64697-4","article-title":"Gammaherpesviruses and \u201cHit-and-Run\u201d oncogenesis","volume":"156","author":"Ambinder","year":"2000","journal-title":"Am J Pathol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.1182\/blood-2003-05-1683","article-title":"Molecular histogenesis of posttransplantation lymphoproliferative disorders","volume":"102","author":"Capello","year":"2003","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/hon.751","article-title":"Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis","volume":"23","author":"Capello","year":"2005","journal-title":"Hematol Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1043\/1543-2165(","article-title":"The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders","volume":"131","author":"Tsao","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1046\/j.1600-6143.2003.00325.x","article-title":"Lymphomas after solid organ transplantation: a collaborative transplant study report","volume":"4","author":"Opelz","year":"2004","journal-title":"Am J Transplant"},{"key":"B14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/TP.0b013e3182200e8a","article-title":"Racial variation in the development of posttransplant lymphoproliferative disorders after renal transplantation","volume":"92","author":"Nee","year":"2011","journal-title":"Transplantation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/00007890-200104270-00010","article-title":"Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)","volume":"71","author":"Dharnidharka","year":"2001","journal-title":"Transplantation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1097\/01.tp.0000179639.98338.39","article-title":"Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression","volume":"80","author":"Caillard","year":"2005","journal-title":"Transplantation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/s0140-6736(05)80084-4","article-title":"Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients","volume":"342","author":"Opelz","year":"1993","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.1182\/blood-2008-09-178046","article-title":"Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11908-010-0145-9","article-title":"Posttransplant lymphoproliferative disease in liver transplant patients","volume":"13","author":"Hartmann","year":"2011","journal-title":"Curr Infect Dis Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1034\/j.1399-3062.2001.003002070.x","article-title":"Identifying the patient at risk for post-transplant lymphoproliferative disorder","volume":"3","author":"Cockfield","year":"2001","journal-title":"Transpl Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/j.1600-6143.2011.03454.x","article-title":"Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients","volume":"11","author":"Reshef","year":"2011","journal-title":"Am J Transplant"},{"key":"B22","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","article-title":"Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial","volume":"13","author":"Trappe","year":"2012","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3389\/fonc.2019.00109","article-title":"Epstein Barr virus associated B-cell lymphomas and iatrogenic lymphoproliferative disorders","volume":"9","author":"Crombie","year":"2019","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1111\/ajt.13324","article-title":"The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder","volume":"15","author":"Luskin","year":"2015","journal-title":"Am J Transplant"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1182\/blood-2015-05-615872","article-title":"How I treat posttransplant lymphoproliferative disorders","volume":"126","author":"Dierickx","year":"2015","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1365-2141.2006.06114.x","article-title":"Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas","volume":"134","author":"Rinaldi","year":"2006","journal-title":"Br J Haematol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.1365-2141.2010.08125.x","article-title":"Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma","volume":"149","author":"Rinaldi","year":"2010","journal-title":"Br J Haematol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"150835","DOI":"10.1155\/2013\/150835","article-title":"Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?","volume":"2013","author":"Morscio","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/bjh.14633","article-title":"Mutational landscape of B-cell post-transplant lymphoproliferative disorders","volume":"178","author":"Menter","year":"2017","journal-title":"Br J Haematol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/PDM.0b013e31804f54a9","article-title":"Gene expression profiling of Epstein-Barr virus-positive and -negative monomorphic B-cell posttransplant lymphoproliferative disorders","volume":"16","author":"Craig","year":"2007","journal-title":"Diagn Mol Pathol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/ajt.13558","article-title":"EBV-positive and EBV-negative posttransplant diffuse large B cell lymphomas have distinct genomic and transcriptomic features","volume":"16","author":"Ferreiro","year":"2016","journal-title":"Am J Transplant"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12307-018-00219-5","article-title":"The tumor microenvironment in post-transplant lymphoproliferative disorders","volume":"12","author":"Marcelis","year":"2019","journal-title":"Cancer Microenviron"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1111\/ajt.13375","article-title":"Epstein-Barr virus modulates host cell microRNA-194 to promote IL-10 production and B lymphoma cell survival","volume":"15","author":"Harris-Arnold","year":"2015","journal-title":"Am J Transplant"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1111\/ajt.12858","article-title":"A comprehensive analysis of the cellular and EBV-specific microRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors","volume":"14","author":"Fink","year":"2014","journal-title":"Am J Transplant"},{"key":"B35","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1600-6143.2010.03387.x","article-title":"Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(bigstar)","volume":"11","author":"Reshef","year":"2011","journal-title":"Am J Transplant"},{"key":"B36","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/01.tp.0000163288.98419.0d","article-title":"Characteristic pattern of chromosomal imbalances in posttransplantation lymphoproliferative disorders: correlation with histopathological subcategories and EBV status","volume":"80","author":"Poirel","year":"2005","journal-title":"Transplantation"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/ajt.15216","article-title":"Dual blockade of the PI3K\/Akt\/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival","volume":"19","author":"Sang","year":"2019","journal-title":"Am J Transplant"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/ajt.12196","article-title":"Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders","volume":"13","author":"Morscio","year":"2013","journal-title":"Am J Transplant"},{"key":"B39","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24","volume":"116","author":"Green","year":"2010","journal-title":"Blood."},{"key":"B41","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1182\/blood-2009-12-257345","article-title":"Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome","volume":"116","author":"Steidl","year":"2010","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1182\/blood-2010-06-291310","article-title":"JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma","volume":"117","author":"Van Roosbroeck","year":"2011","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/S2352-3026(14)00039-8","article-title":"Non-invasive detection of genomic imbalances in Hodgkin\/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study","volume":"2","author":"Vandenberghe","year":"2015","journal-title":"Lancet Haematol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/his.13857","article-title":"Clinicopathological evaluation of the programmed cell death 1 (PD1)\/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome","volume":"75","author":"Veloza","year":"2019","journal-title":"Histopathology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1158\/1541-7786.MCR-13-0350","article-title":"The molecular balancing act of p16(INK4a) in cancer and aging","volume":"12","author":"LaPak","year":"2014","journal-title":"Mol Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0092-8674(00)81079-x","article-title":"Role of the INK4a locus in tumor suppression and cell mortality","volume":"85","author":"Serrano","year":"1996","journal-title":"Cell"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1182\/blood-2004-03-1209","article-title":"Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome","volume":"104","author":"Barrans","year":"2004","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/sj.leu.2403813","article-title":"FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations","volume":"19","author":"Wlodarska","year":"2005","journal-title":"Leukemia"},{"key":"B52","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1517\/14728222.11.7.955","article-title":"FOXP1: a potential therapeutic target in cancer","volume":"11","author":"Koon","year":"2007","journal-title":"Expert Opin Ther Targets"},{"key":"B53","doi-asserted-by":"publisher","first-page":"11096","DOI":"10.1128\/JVI.01069-12","article-title":"Analysis of Epstein-Barr virus-regulated host gene expression changes through primary B-cell outgrowth reveals delayed kinetics of latent membrane protein 1-mediated NF-kappaB activation","volume":"86","author":"Price","year":"2012","journal-title":"J Virol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e85851","DOI":"10.1371\/journal.pone.0085851","article-title":"Non-IG aberrations of FOXP1 in B-cell malignancies lead to an aberrant expression of N-truncated isoforms of FOXP1","volume":"9","author":"Rouhigharabaei","year":"2014","journal-title":"PLoS ONE"},{"key":"B55","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1099\/0022-1317-83-1-173","article-title":"Expansion in scid mice of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease biopsy material","volume":"83","author":"Johannessen","year":"2002","journal-title":"J Gen Virol."},{"key":"B56","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.4049\/jimmunol.158.9.4045","article-title":"Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines","volume":"158","author":"Beatty","year":"1997","journal-title":"J Immunol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1097\/00007890-199903270-00015","article-title":"Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation","volume":"67","author":"Birkeland","year":"1999","journal-title":"Transplantation"},{"key":"B58","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1046\/j.1365-2141.2003.04540.x","article-title":"Epstein-Barr virus (EBV) load and interleukin-10 in EBV-positive and EBV-negative post-transplant lymphoproliferative disorders","volume":"122","author":"Muti","year":"2003","journal-title":"Br J Haematol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/10428190400027837","article-title":"Epstein-Barr viral load, interleukin-6 and interleukin-10 levels in post-transplant lymphoproliferative disease: a nested case-control study in a renal transplant cohort","volume":"46","author":"Baiocchi","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"B60","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/j.1432-2277.2011.01282.x","article-title":"IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: a longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment","volume":"24","author":"Hinrichs","year":"2011","journal-title":"Transpl Int"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1182\/blood-2006-01-024703","article-title":"A phase 1\/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies","volume":"109","author":"Perrine","year":"2007","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-15-2242","article-title":"Lenalidomide, thalidomide, and pomalidomide reactivate the Epstein-Barr virus lytic cycle through phosphoinositide 3-kinase signaling and ikaros expression","volume":"22","author":"Jones","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"13052","DOI":"10.1038\/s41598-017-13533-7","article-title":"Bortezomib promotes KHSV and EBV lytic cycle by activating JNK and autophagy","volume":"7","author":"Granato","year":"2017","journal-title":"Sci Rep"},{"key":"B64","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.3390\/v2102213","article-title":"Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate","volume":"2","author":"Hostetler","year":"2010","journal-title":"Viruses"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJM199404283301703","article-title":"Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation","volume":"330","author":"Papadopoulos","year":"1994","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1182\/blood-2016-01-628982","article-title":"T cells for viral infections after allogeneic hematopoietic stem cell transplant","volume":"127","author":"Bollard","year":"2016","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e1139274","DOI":"10.1080\/2162402X.2016.1139274","article-title":"Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation","volume":"5","author":"Jiang","year":"2016","journal-title":"Oncoimmunology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1182\/blood-2015-02-567453","article-title":"Immune checkpoint blockade in hematologic malignancies","volume":"125","author":"Armand","year":"2015","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1080\/10428194.2018.1480767","article-title":"Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation","volume":"60","author":"Kinch","year":"2019","journal-title":"Leuk Lymphoma"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00506\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T20:42:48Z","timestamp":1696106568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00506\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,8]]},"references-count":70,"alternative-id":["10.3389\/fonc.2020.00506"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00506","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,8]]},"article-number":"506"}}